Avoro Capital Advisors Reduces $95M in Atrium Therapeutics, Inc. ($RNA)
Avoro Capital Advisors has completely exited its position in RNA.
Key Points
- Avoro Capital Advisors sold all 7,645,000 shares of RNA, reducing its stake by 100% as of the latest 13F filing.
- RNA shares traded at $12.37, with insider buying activity reported by several key executives.
- Analysts initiated coverage with buy ratings, with price targets set at $25, while insiders acquired shares on April 20, 2026.
Avoro Capital Advisors has fully exited its investment in RNA, selling all 7,645,000 shares it previously held. This move, reported in its latest 13F filing with the SEC, reflects a complete 100% reduction in its position.
What Changed in Avoro Capital Advisors' RNA Position
Avoro Capital Advisors sold off its entire holding of 7,645,000 shares in RNA, completely eliminating its stake. This action is documented in the firm's latest 13F filing, indicating a complete exit from the stock.
Other Institutional Activity in RNA
Other major funds have also adjusted their positions in RNA. Price T Rowe Associates Inc grew its holdings significantly by 1,410,322 shares, ending with 1,553,210 shares worth about $20.77 million. BlackRock, Inc., on the other hand, reduced its position by 11,645,510 shares, leaving it with 1,205,291 shares valued at approximately $16.11 million. Similarly, RA Capital Management, L.P. cut its stake by 7,776,929 shares, holding 864,102 shares valued at $11.55 million. Meanwhile, Vanguard Capital Management LLC and TIG Advisors, LLC both initiated positions with 626,869 and 607,552 shares respectively.
RNA Stock Snapshot
Shares of RNA are currently trading at $12.37. The stock has seen a range of institutional activity, with significant buying and selling from major funds. The recent insider buying activity and new analyst coverage could play a role in its future performance.
Insider Buying and Selling at Atrium Therapeutics, Inc.
On April 20, 2026, several RNA executives made significant stock purchases. Chief Strategy Officer Rocio Martin Hoyos acquired 60,000 shares, while CEO Kathleen Gallagher purchased 102,500 shares. Other key executives, including Chief Medical Officer Steven George Hughes and Chief Corporate Affairs Officer Stephanie Kenney, each bought 30,000 shares. These transactions were not part of any pre-planned trading program.
Analysts Set New Price Targets
On May 15, 2026, Leerink Partners initiated coverage of RNA with a buy rating and a $25 price target. Wells Fargo also started coverage on March 11, 2026, with a similar buy rating and price target. These new targets reflect positive sentiment from analysts, despite some prior downgrades to hold ratings from other firms.
About RNA
RNA is a biotechnology company focused on developing innovative therapies. The firm is engaged in research and development to create treatments that address unmet medical needs. RNA operates within the broader healthcare sector, striving to advance its pipeline of potential therapies.
Bottom Line
Avoro Capital Advisors' complete exit from RNA marks a significant shift in its investment strategy. While the 13F filing provides a snapshot of past holdings, it doesn't necessarily reflect the firm's current or future positions. Investors keep an eye on such filings to gauge institutional sentiment and market dynamics.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.